Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the MTD of Mg pidolate in combination with HU in
patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU
for at least 6 months.